---
title: "ProPhase Labs Issues Update on Crown Medical Collections"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273870076.md"
description: "ProPhase Labs (PRPH) has provided an operational update regarding its Crown Medical Collections initiative, which involves legacy COVID-19 testing receivables amid Chapter 11 proceedings. This update is crucial for security holders due to its potential impact on financial recoveries. Currently, analysts rate PRPH stock as a Sell with a $0.24 price target, reflecting concerns over weak financial performance and a bearish technical trend. The stock has a market cap of $1.25M and an average trading volume of 1,174,898."
datetime: "2026-01-27T16:27:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273870076.md)
  - [en](https://longbridge.com/en/news/273870076.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273870076.md)
---

# ProPhase Labs Issues Update on Crown Medical Collections

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Prophase Labs ( (PRPH) ) has issued an update.

On January 26, 2026, ProPhase Labs, Inc. announced it had issued an operational update on the progress of its Crown Medical Collections initiative, which concerns legacy COVID-19 testing receivables tied to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The update underscores the company’s ongoing efforts to address and manage outstanding pandemic-era testing receivables in the context of its subsidiaries’ bankruptcy process, an issue of material importance to its security holders given the potential impact on recoveries and financial positioning.

The most recent analyst rating on (PRPH) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

**Spark’s Take on PRPH Stock**

According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.

The score is held down primarily by weak financial performance (sharp revenue decline, ongoing losses, and negative operating/free cash flow) and a bearish technical trend. Offsetting this somewhat is a mixed but potentially catalyst-driven earnings-call backdrop (claims collections and asset/partner optionality), while valuation is difficult to support with a negative P/E and no dividend.

To see Spark’s full report on PRPH stock, click here.

**More about Prophase Labs**

**Average Trading Volume:** 1,174,898

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $1.25M

### Related Stocks

- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PRPH.US](https://longbridge.com/en/quote/PRPH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)
- [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md)
- [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md)
- [Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US](https://longbridge.com/en/news/293415324.md)